Bor-wen Wu, Phd, Mba

Biography

 Bor-Wen Wu spent 13 years as a biochemist at Agouron Pharmaceuticals, Inc., Warner-Lambert, and Pfizer. He worked mainly on HIV-related projects and, as a member of a structure-based drug design team, made significant contribution to the development of Viracept, an HIV protease inhibitor that was approved in 1996. In 2002, he founded DesigneRx Pharmaceuticals, Inc., a pilot cGMP facility for biologics in California. In 2003, he founded TDW Pharmaceuticals, Inc., a Taiwan-based pharmaceutical company developing treatments for cancer and gout. In 2004, he put together a group of investors to purchase Phoenix Pharmacologics, Inc., a company developing ADI-PEG 20, a promising novel biologics for cancers. In 2008, he co-founded Polaris Group and Polaris Pharmaceuticals, Inc. to continue the clinical development of ADI-PEG 20. Dr. Wu earned his Ph.D. in Molecular Biology and Biochemistry from the University of California, Irvine.

Research Interest

 Molecular Biology and Biochemistry